滤泡性淋巴瘤中的Smad1表达

Smad1 expression in follicular lymphoma.

作者信息

Go Jai Hyang

机构信息

Department of Pathology, Dankook University College of Medicine, Cheonan, Korea.

出版信息

J Pathol Transl Med. 2015 May;49(3):243-8. doi: 10.4132/jptm.2015.03.30. Epub 2015 May 15.

DOI:10.4132/jptm.2015.03.30

PMID:26018516

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4440936/

Abstract

BACKGROUND

Follicular lymphomas present with various immunohistologic patterns. The immunohistochemical markers used in the diagnosis of follicular lymphoma show variable degrees of sensitivity and specificity, and thus, additional germinal center markers are required. Smad1 has been reported to be overexpressed in follicular lymphoma, but little is known regarding the expression patterns of Smad proteins in human lymphoid tissue.

METHODS

In the present study, we performed immunohistochemistry for traditional germinal center markers and for Smad1 in human reactive lymphoid and follicular lymphoma tissues to investigate Smad1's usefulness in the diagnosis of follicular lymphoma.

RESULTS

In the reactive germinal centers, most cells were positive for Smad1. Among the 27 follicular lymphoma cases, 17 of 21 (80%) were Smad1 positive, 17 of 27 (63%) were positive for CD10, and 23 of 27 (85%) were positive for Bcl6. Notably, three cases expressed CD10 only, and one only expressed Bcl6. All these cases were grade 3 tumors and showed follicular and diffuse growth patterns.

CONCLUSIONS

These results indicate that Smad1 is a candidate as a germinal center marker. Furthermore, they suggest that the Smad signaling pathway might be involved in follicular lymphoma.

摘要

背景

滤泡性淋巴瘤呈现出多种免疫组织学模式。用于诊断滤泡性淋巴瘤的免疫组化标志物显示出不同程度的敏感性和特异性，因此，需要额外的生发中心标志物。据报道，Smad1在滤泡性淋巴瘤中过表达，但关于Smad蛋白在人类淋巴组织中的表达模式知之甚少。

方法

在本研究中，我们对人类反应性淋巴组织和滤泡性淋巴瘤组织中的传统生发中心标志物和Smad1进行了免疫组化，以研究Smad1在滤泡性淋巴瘤诊断中的作用。

结果

在反应性生发中心，大多数细胞Smad1呈阳性。在27例滤泡性淋巴瘤病例中，21例中的17例（80%）Smad1呈阳性，27例中的17例（63%）CD10呈阳性，27例中的23例（85%）Bcl6呈阳性。值得注意的是，3例仅表达CD10，1例仅表达Bcl6。所有这些病例均为3级肿瘤，表现为滤泡性和弥漫性生长模式。